Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of North Carolina
PROTOCOL OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.
Arm I: Patients receive oral hydroxyurea and oral clotrimazole daily for 12 months.
Arm II: Patients receive oral hydroxyurea daily for 12 months. Patients are followed at 6 weeks.
Completion date provided represents the completion date of the grant per OOPD records
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PROTOCOL ENTRY CRITERIA:
-Disease Characteristics--
Diagnosis of sickle cell anemia confirmed by hemoglobin electrophoresis
Received hydroxyurea for at least 6 months On a stable dose for at least 3 months Tolerating dose of at least 5 mg/kg/day
-Prior/Concurrent Therapy--
Chemotherapy:
No other concurrent antisickling agent
Other: No concurrent drug that may interact with or influence the metabolism of hydroxyurea or clotrimazole
-Patient Characteristics--
Hematopoietic: WBC at least 4000/mm3 Platelet count at least 150,000/mm3 Hemoglobin less than 11 g/dL
Hepatic: AST/ALT no greater than 100 units/L
Renal: Creatinine no greater than 1.5 mg/dL
Other:
Not pregnant or nursing
Fertile patients must use effective contraception
No prior adverse reaction to hydroxyurea or clotrimazole